Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of 99mTc-rhAnnexin V-128 in Healthy Volunteers
NCT02182609Phase 1Completed
- Sponsor
- Advanced Accelerator Applications
- Start
- Apr 2013
- Primary completion
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of technetium-tc99m-labeled annexin a5, sponsored by Advanced Accelerator Applications. Primary endpoints: Adverse events, Laboratory assessments at 30 days and 2 more. Started Apr 2013; status: completed.
02
Drugs
technetium-tc99m-labeled annexin a5
Beyond the preview
Go deeper on NCT02182609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182609.